Navigation Links
Daily Aspirin May Reduce Breast Cancer Risk
Date:5/1/2008

But findings are too preliminary for any firm recommendation, researchers say

THURSDAY, May 1 (HealthDay News) -- Women who take an aspirin each day may reduce their risk of developing the most common type of breast cancer by 16 percent, according to the results of a large study.

Estrogen receptor-positive breast cancer accounts for some 75 percent of all breast cancers, experts say. While aspirin reduced the risk of this form of breast malignancy, other painkillers did not, the U.S. team found.

"Many studies have looked at the relationship between nonsteroidal anti-inflammatory drugs (NSAIDs) and cancer, and the results have been all over the board," said lead researcher Gretchen Gierach, a cancer prevention fellow at the U.S. National Cancer Institute. "We want to further examine the question to see if we can add some clarity, since studies have looked at NSAIDs but haven't broken them down by type of NSAID."

The report is published in the April 30 online edition of Breast Cancer Research.

In the study, Gierach's team collected data on more than 127,000 women aged 51 to 72 with no history of cancer. All had participated in the U.S. National Institutes of Health-AARP Diet and Health Study. That study was designed to look at diet, health-related behaviors, and the risk for cancer.

Gierach noted that aspirin does has different biological effects compared to other NSAIDs.

Aspirin is one of many NSAIDs but unlike other NSAIDs it has irreversible effects on cyclooxygenase (COX) enzymes. For this reason, the researchers looked at the differences in cancer risk based on whether women took aspirin or other NSAIDs.

"Among women who reported taking aspirin on a daily basis there was a modest reduction in estrogen receptor-positive breast cancer," Gierach said.

Overall, NSAIDs did not affect the total risk of breast cancer. However, the daily use of aspirin was associated with a 16 percent reduction in the risk for estrogen receptor-positive breast tumors.

There was no link between daily aspirin and the incidence of estrogen receptor-negative breast cancer, the researchers report.

The finding could have important implications for cancer prevention, Gierach says, but a lot more work is needed to see if the effect is real. Moreover, she believes that it is still too early to recommend that women start taking aspirin to prevent breast malignancy.

"This is an exciting implication, if it's true," Gierach said. "But we need further clarity from other studies."

One expert noted that chronic aspirin use can have serious consequences and should not be used for cancer prevention.

"The American Cancer Society does not recommend using aspirin for cancer prevention because aspirin can cause serious gastrointestinal bleeding," said Eric J. Jacobs, Strategic Director of Pharmacoepidemiology in the department of epidemiology and surveillance research at the American Cancer Society.

Whether or not you should use aspirin for disease prevention is a question that should be discussed with your doctor, who can take your medical history into account, Jacobs said. "This decision should be based on balancing the proven benefits of aspirin in preventing heart disease against the proven risks of serious gastrointestinal bleeding," he said.

Another expert was intrigued by the findings.

"This theory has been around for many years," said Barbara Brenner, executive director of Breast Cancer Action. "If this works, it is a very exciting development for a lot of people who are thinking about how we can control not only cancer, but the price of cancer drugs."

The finding is confirming what many people have thought for a long time, Brenner added. But she stressed that aspirin would not be "a cure-all, it's only reducing the risk of estrogen positive-breast cancer."

Like the other experts, Brenner doesn't advise women to start taking aspirin to prevent breast cancer. "There are risks with aspirin, and there are people for whom aspirin is not indicated," she said. "But they might want to talk to their doctors about this study and whether aspirin is appropriate for them."

More information

For more information on breast cancer, visit the U.S. National Cancer Institute .



SOURCES: Gretchen Gierach Ph.D., cancer prevention fellow, U.S. National Cancer Institute, Rockville, Md.; Eric J. Jacobs, Ph.D., Strategic Director, Pharmacoepidemiology, Department of Epidemiology and Surveillance Research, American Cancer Society, Atlanta; Barbara Brenner, executive director, Breast Cancer Action, San Francisco; April 30, 2008, Breast Cancer Research


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Daily aspirin may reduce risk of common type of breast cancer
2. Smiles. Made Fresh Daily
3. FDA approves VYVANSE, first and only once-daily prodrug stimulant to treat ADHD in adults
4. Labopharm Appeals FDAs Decision on Once-Daily Tramadol to Next Supervisory Level After Additional Analysis Supports Efficacy
5. Once-Daily Insulin Shot Proves Effective in Study
6. U.S. Census Bureau Daily Feature for March 15
7. Labopharm Initiates Phase III Clinical Trial for Twice-Daily Formulation of Tramadol-Acetaminophen
8. U.S. Census Bureau Black History Month Daily Feature for February 27
9. A Once-Daily Oral Drug for Chronic Obstructive Pulmonary Disease That Treats COPD-Related Inflammation Could Achieve Blockbuster Status
10. HIV Drug in Microbicide Gel Safe for Daily Use
11. Trial finds tenofovir gel safe for daily use and most women adhered to study regimens
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Daily Aspirin May Reduce Breast Cancer Risk
(Date:2/26/2017)... ... February 26, 2017 , ... ODH, Inc.™ announced today it will exhibit ... Sheraton Pentagon City Hotel in Arlington, VA. ODH’s director of medical strategy, Candace Saldarini, ... to improve Medicaid population health management. , ODH will also have an exhibit booth ...
(Date:2/25/2017)... ... February 25, 2017 , ... FCPX users now have the ability to ... Studios. With ProSharpen Color users have total control over sharpening amount, sharpening radius, threshold, ... With color spectrum tools users can visually see the color range effected with ease ...
(Date:2/24/2017)... ... ... Only two months after the official release of The Private Collection – Edition 2017 ... initiated a second print-run of its lavish luxury travel coffee table book. , ... in at more than six kilos, retails at EUR 1,000 per copy and is ...
(Date:2/24/2017)... ... , ... Dr. Ronald E. Hawkins, vice president for academic ... A. Bell, DO, MBA, HPF, FACOEP-dist., FACEP, as the new dean of ... comes to Liberty from the Ohio University Heritage College of Osteopathic Medicine (OU-HCOM), ...
(Date:2/24/2017)... (PRWEB) , ... February 24, 2017 , ... ... and hearing disabilities, it is so critically important that we all are aware ... That is why Mediaplanet is proud to announce the launch of its newest ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... ITL Limited, ( ASX : ITD ), une société de ... excellents résultats semestriels clos le 31 décembre 2016 par ... « Résultats et mise à jour sur la croissance biomédicale ... Faits marquants Bénéfice ... hausse de 104 %) Bénéfice par action ...
(Date:2/24/2017)... 23, 2017 Non-alcoholic steatohepataitis (NASH) ... various drugs being developed for the treatment ... drugs that are in various phases of ... focuses on novel pharmacologic drugs & regenerative ... therapies, recombinant proteins and RNA-based therapeutics, but ...
(Date:2/24/2017)... Feb. 24, 2017  Xynomic Pharmaceuticals, Inc., an oncology ... it has acquired exclusive worldwide rights to develop, ... HDAC inhibitor targeting hematological and solid tumors. ... 1 and 2 clinical trials of Abexinostat in ... have already been completed, demonstrating that Abexinostat is ...
Breaking Medicine Technology: